AU2004247721C1 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor - Google Patents

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor Download PDF

Info

Publication number
AU2004247721C1
AU2004247721C1 AU2004247721A AU2004247721A AU2004247721C1 AU 2004247721 C1 AU2004247721 C1 AU 2004247721C1 AU 2004247721 A AU2004247721 A AU 2004247721A AU 2004247721 A AU2004247721 A AU 2004247721A AU 2004247721 C1 AU2004247721 C1 AU 2004247721C1
Authority
AU
Australia
Prior art keywords
compound
formula
dihydro
inden
indazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004247721A
Other languages
English (en)
Other versions
AU2004247721B2 (en
AU2004247721A1 (en
Inventor
Erol K. Bayburt
Gilles Chambournier
Russel D. Cink
Arthur Gomtsyan
Margaret Hsu
John R. Koenig
M. Robert Leanna
Chih-Hung Lee
Kirill Lukin
Robert Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33555102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004247721(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/459,925 external-priority patent/US7015233B2/en
Priority claimed from US10/864,068 external-priority patent/US7375126B2/en
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of AU2004247721A1 publication Critical patent/AU2004247721A1/en
Priority to AU2010257277A priority Critical patent/AU2010257277B2/en
Application granted granted Critical
Publication of AU2004247721B2 publication Critical patent/AU2004247721B2/en
Publication of AU2004247721C1 publication Critical patent/AU2004247721C1/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. Request for Assignment Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2004247721A 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor Ceased AU2004247721C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010257277A AU2010257277B2 (en) 2003-06-12 2010-12-17 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/459,925 2003-06-12
US10/459,925 US7015233B2 (en) 2003-06-12 2003-06-12 Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US10/864,068 2004-06-09
US10/864,068 US7375126B2 (en) 2003-06-12 2004-06-09 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
PCT/US2004/018590 WO2004111009A1 (en) 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010257277A Division AU2010257277B2 (en) 2003-06-12 2010-12-17 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Publications (3)

Publication Number Publication Date
AU2004247721A1 AU2004247721A1 (en) 2004-12-23
AU2004247721B2 AU2004247721B2 (en) 2011-01-20
AU2004247721C1 true AU2004247721C1 (en) 2011-12-22

Family

ID=33555102

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004247721A Ceased AU2004247721C1 (en) 2003-06-12 2004-06-10 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2010257277A Ceased AU2010257277B2 (en) 2003-06-12 2010-12-17 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010257277A Ceased AU2010257277B2 (en) 2003-06-12 2010-12-17 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Country Status (20)

Country Link
EP (2) EP2017265B1 (enExample)
JP (2) JP4857113B2 (enExample)
KR (2) KR101138216B1 (enExample)
CN (1) CN102617464A (enExample)
AT (2) ATE411982T1 (enExample)
AU (2) AU2004247721C1 (enExample)
BR (1) BRPI0411116A (enExample)
CA (2) CA2756058A1 (enExample)
CY (2) CY1108713T1 (enExample)
DE (1) DE602004017329D1 (enExample)
DK (2) DK2017265T3 (enExample)
ES (1) ES2318308T3 (enExample)
IL (4) IL172457A (enExample)
MX (1) MXPA05013550A (enExample)
NZ (3) NZ590234A (enExample)
PL (2) PL2017265T3 (enExample)
PT (2) PT1658269E (enExample)
SI (2) SI2017265T1 (enExample)
TW (3) TWI366461B (enExample)
WO (1) WO2004111009A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
US7612200B2 (en) 2004-12-07 2009-11-03 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
EP1931681B1 (en) 2005-10-07 2012-11-14 Glenmark Pharmaceuticals S.A. Substituted benzofused derivatives and their use as vanilloid receptor ligands
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
AU2006306146A1 (en) * 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
AU2007238071B2 (en) * 2006-04-18 2012-06-07 Abbvie Inc. Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2009081222A1 (en) 2007-12-21 2009-07-02 Glenmark Pharmaceuticals, S.A. Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands
WO2009096701A2 (en) 2008-01-28 2009-08-06 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP5438103B2 (ja) 2008-07-02 2014-03-12 アモーレパシフィック コーポレイション バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物
UY32180A (es) * 2008-10-17 2010-05-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
NZ618795A (en) 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
BR112014027644A2 (pt) * 2012-05-09 2017-06-27 Bayer Cropscience Ag 5-halogenopirazol-indanil-carboxamidas
ME02990B (me) 2012-11-13 2018-10-20 Array Biopharma Inc Jedinjenja n-pirolidinil, n'-pirazolil- uree, tiouree, guanidina i cijanoguanidina kао inhibitori trka kinaze
CA2891334C (en) 2012-11-13 2021-10-19 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CN106459013B (zh) 2014-05-15 2019-10-25 阵列生物制药公司 作为trka激酶抑制剂的化合物及其用途
CA3022432A1 (en) * 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014064A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW536734B (en) * 2000-07-31 2003-06-11 Clariant Int Ltd Process for manufacturing a microelectronic device
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003241453A1 (en) * 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014064A1 (en) * 2001-07-31 2003-02-20 Bayer Healthcare Ag Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D2: D.LANDSIEDEL-MAIER: "Structure activity relationship of homochiral 7-substituted 1-aminoindans as 5-HT1 A receptor ligands" ARCHIV DER PHARMAZIE, vol. 331, 1998, pages 59-71, XP002296522; *
D3: J STERLING: "Novel dual inhibitors of AchE and MAO" JOURNAL FOR MEDICINAL CHEMISTRY, vol. 45, no. 24, 2002, pages 5260-5279, XP002296523. *

Also Published As

Publication number Publication date
TWI366461B (en) 2012-06-21
PL1658269T3 (pl) 2009-08-31
IL172457A (en) 2011-12-29
CN102617464A (zh) 2012-08-01
CA2756058A1 (en) 2004-12-23
ATE510824T1 (de) 2011-06-15
MXPA05013550A (es) 2006-04-05
AU2010257277A1 (en) 2011-01-13
JP2011153148A (ja) 2011-08-11
BRPI0411116A (pt) 2006-07-18
PT2017265E (pt) 2011-07-29
TW200509926A (en) 2005-03-16
PT1658269E (pt) 2009-01-09
PL2017265T3 (pl) 2011-11-30
IL215997A0 (en) 2011-12-29
IL172457A0 (en) 2006-04-10
KR101138216B1 (ko) 2012-09-05
JP2007500753A (ja) 2007-01-18
TW201300361A (zh) 2013-01-01
KR20110089464A (ko) 2011-08-08
CY1111945T1 (el) 2015-11-04
IL216046A0 (en) 2011-12-29
IL207335A0 (en) 2010-12-30
NZ543713A (en) 2009-08-28
HK1126488A1 (en) 2009-09-04
ATE411982T1 (de) 2008-11-15
TW201038269A (en) 2010-11-01
SI1658269T1 (sl) 2009-04-30
EP2017265A1 (en) 2009-01-21
TWI394569B (zh) 2013-05-01
AU2004247721B2 (en) 2011-01-20
EP1658269B1 (en) 2008-10-22
HK1093727A1 (en) 2007-03-09
JP4857113B2 (ja) 2012-01-18
KR101150324B1 (ko) 2012-06-13
KR20060058769A (ko) 2006-05-30
CY1108713T1 (el) 2014-04-09
SI2017265T1 (sl) 2011-09-30
NZ578264A (en) 2011-02-25
WO2004111009A1 (en) 2004-12-23
AU2010257277B2 (en) 2011-08-18
NZ590234A (en) 2012-07-27
DE602004017329D1 (de) 2008-12-04
DK1658269T3 (da) 2009-01-12
DK2017265T3 (da) 2011-09-19
CA2526872C (en) 2013-02-05
EP1658269A1 (en) 2006-05-24
AU2004247721A1 (en) 2004-12-23
IL207335A (en) 2012-02-29
EP2017265B1 (en) 2011-05-25
CA2526872A1 (en) 2004-12-23
ES2318308T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
AU2004247721B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US8071762B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1660455B1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US20030158188A1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7375126B2 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2011244937A1 (en) Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
HK1129383A (en) Fused compounds that inhibit vanilloid receptor subtype1(vr1) receptor
HK1093727B (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
HK1126488B (en) Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JUN 2011.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 JUN 2011

PC Assignment registered

Owner name: ABBVIE INC.

Free format text: FORMER OWNER WAS: ABBOTT LABORATORIES

MK14 Patent ceased section 143(a) (annual fees not paid) or expired